Nawrot Ireneusz, Woźniewicz Bogdan, Tołłoczko Tadeusz, Sawicki Andrzej, Górski Andrzej, Chudziński Witold, Wojtaszek Mikołaj, Grzesiuk Wiesław, Sladowski Dariusz, Karwacki Jerzy, Zawitkowska Teresa, Szmidt Jacek
Department of General, Vascular, and Transplantation Surgery, The Medical University of Warsaw, Warsaw, Poland.
Transplantation. 2007 Mar 27;83(6):734-40. doi: 10.1097/01.tp.0000258601.17505.9d.
Hypoparathyroidism is a well-known consequence of extensive thyroid and parathyroid surgery. Allotransplantation of cultured parathyroid cells can be considered as an alternative to vitamin D3 and calcium supplementation in treatment of hypoparathyroidism. We present the long-term allotransplant activity in 85 patients who had undergone cellular allotransplantation for surgical hypoparathyroidism. Also, a modified technique to prepare parathyroid explants is described for obtaining a new nonimmunogenic cell population.
From March 1990 to December 2004, 85 patients underwent 116 allotransplantations of cultured parathyroid cells. Mean recipient age was 46.2+/-11.1 years. Donors were selected from patients undergoing parathyroidectomy for secondary and tertiary hyperparathyroidism.
After 6 weeks of cultivation and freezing, the parathyroid cells decreased their normal human leukocyte antigen (HLA) class I ABC expression and were free of HLA class II positive cells. The viability of cultured cells was 95.15+/-2.94%. Eighty-five patients underwent primary allotransplantation. Of these, 25 patients subsequently underwent a repeat procedure. In six cases, the parathyroid cells were obtained from the same donor and in 19 cases from a different donor. For all patients, the mean cellular allograft survival was 6.35+/-13.08 months. In 64 patients (55.1%), the allografts retained their endocrine function for more than 2 months.
The present study has shown that in some patients parathyroid cell allotransplantation may be considered a method of treatment for permanent hypoparathyroidism after thyroid surgery. Graft function and/or survival did not depend on the baseline viability or secretory activity of cultured cells used for transplantation.
甲状旁腺功能减退是广泛的甲状腺和甲状旁腺手术的一个众所周知的后果。培养的甲状旁腺细胞同种异体移植可被视为治疗甲状旁腺功能减退时维生素D3和钙补充剂的一种替代方法。我们展示了85例因手术导致甲状旁腺功能减退而接受细胞同种异体移植患者的长期同种异体移植活性。此外,还描述了一种改良的制备甲状旁腺外植体的技术,以获得新的非免疫原性细胞群体。
1990年3月至2004年12月,85例患者接受了116次培养的甲状旁腺细胞同种异体移植。受体的平均年龄为46.2±11.1岁。供体选自因继发性和三发性甲状旁腺功能亢进而接受甲状旁腺切除术的患者。
经过6周的培养和冷冻,甲状旁腺细胞降低了其正常的人类白细胞抗原(HLA)I类ABC表达,且没有HLA II类阳性细胞。培养细胞的活力为95.15±2.94%。85例患者接受了初次同种异体移植。其中,25例患者随后接受了重复手术。6例中,甲状旁腺细胞来自同一供体,19例来自不同供体。所有患者的平均细胞同种异体移植存活时间为6.35±13.08个月。64例患者(55.1%)的同种异体移植保留内分泌功能超过2个月。
本研究表明,在一些患者中,甲状旁腺细胞同种异体移植可被视为甲状腺手术后永久性甲状旁腺功能减退的一种治疗方法。移植物功能和/或存活不依赖于用于移植的培养细胞的基线活力或分泌活性。